Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02751879 · ClinicalTrials.gov registry record

Real World Data on Gi(l)Otrif® Dose Adjustment

A clinical trial of Carcinoma, Non-Small Cell Lung, sponsored by Boehringer Ingelheim.

Completed
Registry status
228
Enrollment target
20
Study locations

NCT02751879 is a study of Carcinoma, Non-Small Cell Lung that has completed, run by Boehringer Ingelheim. The registered enrollment target is 228 participants, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02751879, a study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Boehringer Ingelheim.

COMPLETED
Registry status
228 participants
Enrollment target
20
Study locations

Study Summary

This is a non-interventional, multi-country, multi-site study based on existing data from medical records of patients treated with Gi(l)otrif® as part of the routine treatment according to the approved label. Data from real-world will help to understand if dose modifications are done similar as in LUX-Lung 3 trial and if the outcome on safety and effectiveness are as in trial settings. Furthermore, data on modified starting doses, the underlying reasons and effects on safety and outcome are needed.

Conditions Studied

Carcinoma, Non-Small Cell Lung

Study Locations (20)

Other

  • SMZ Baumgartner Hoehe Otto Wagner Spital - Vienna
  • HOP Jean Minjoz - Besançon
  • HOP Dijon, Cardio-Pneumo, Dijon - Dijon
  • HOP Européen G. Pompidou - Paris
  • HOP Tenon - Paris
  • Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH - Essen
  • Klinikum Nürnberg - Nuremberg
  • Pius-Hospital, Oldenburg - Oldenburg
  • Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo - Alessandria
  • Azienda Ospedaliera Vito Fazzi - Lecce
  • Aichi Cancer Center Hospital - Aichi, Nagoya
  • Kurashiki Central Hospital - Okayama, Kurashiki
  • Centro Medico ABC - Mexico City
  • Organización para Cuidado Integral en Oncología S.A de C.V - Monterrey
  • Unidad de Cancerologia - Zapopan
  • Medical Practice,Bogdan Zurawski,Private Practice,Bydgoszcz - Bydgoszcz
  • Grzegorz Czyzewicz Specialised Medical Practice, Cracow - Krakow

New York

  • Montefiore Medical Center - The Bronx

North Carolina

  • Levine Cancer Institute - Charlotte

British Columbia

  • BC Cancer Agency - Vancouver - Vancouver

Trial Details

FieldValue
Enrollment Target 228 participants
Start Date 2016-11-24
Est. Completion 2017-09-30

Sponsor

Boehringer Ingelheim

515 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02751879

The ClinicalTrials.gov registry entry for NCT02751879 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 322-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (29% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 0 interventions.

NCT02751879 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, New York, North Carolina.

Frequently Asked Questions

What is clinical trial NCT02751879 about?

NCT02751879 is a clinical study titled "Real World Data on Gi(l)Otrif® Dose Adjustment". This is a non-interventional, multi-country, multi-site study based on existing data from medical records of patients treated with Gi(l)otrif® as part of the routine treatment according to the approved label. Data from real-world will help to understand if dose modifications are done similar as in L...

What is the current status of trial NCT02751879?

This trial is currently completed. The enrollment target is 228 participants. The study started on 2016-11-24. Estimated completion is 2017-09-30.

What conditions does trial NCT02751879 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.

Who is sponsoring clinical trial NCT02751879?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02751879 being conducted?

This trial has 20 study locations across New York, North Carolina, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.